Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis

被引:28
|
作者
Petrasek, Jan [1 ]
Csak, Timea [1 ]
Ganz, Michal [1 ]
Szabo, Gyongyi [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA
关键词
alcoholic liver disease; alcoholic steatohepatitis; inflammasome; innate immunity; interleukin-1; beta; interleukin-1 receptor antagonist; Kupffer cells; non-alcoholic steatohepatitis; Toll-like receptors; INDUCED LIVER-INJURY; IL-1 RECEPTOR ANTAGONIST; NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTOR-4; DIET-INDUCED OBESITY; RAT KUPFFER CELLS; FATTY LIVER; INTESTINAL PERMEABILITY; HEPATIC STEATOSIS; PLASMA ENDOTOXIN;
D O I
10.1111/jgh.12020
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The similar histopathological characteristics of alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH), and the crucial role of the innate immune response in both conditions may lead to the assumption that ASH and NASH represent the same pathophysiological entities caused by different risk factors. In this review paper, we elaborate on the pathophysiological differences between these two entities and highlight the disease-specific involvement of signaling molecules downstream of the Toll-like receptor 4, and the differential mechanism by which the inflammasome contributes to ASH versus NASH. Our findings emphasize that ASH and NASH have disease-specific mechanisms and therefore represent distinct biological entities. Further studies are needed to dissect the emerging differences in pathogenesis of these two conditions.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 50 条
  • [31] Non-alcoholic steatohepatitis (NASH)
    Michael F. Sorrell
    Sandeep Mukherjee
    Current Treatment Options in Gastroenterology, 1999, 2 (6) : 447 - 450
  • [32] Metformin in non-alcoholic steatohepatitis
    Urso, R
    Visco-Comandini, U
    LANCET, 2002, 359 (9303): : 355 - 356
  • [33] News on non-alcoholic steatohepatitis
    Roeb, E.
    Nitschmann, S.
    INTERNIST, 2022, 63 (02): : 238 - 242
  • [34] Non-alcoholic Steatohepatitis: An Overview
    Shifflet, Allison
    Wu, George Y.
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (01) : 4 - 12
  • [35] Cannabis and non-alcoholic steatohepatitis
    Cohen, L. B.
    Neuman, M. G.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 46 : 51 - 51
  • [36] Familial non-alcoholic steatohepatitis
    Neuman, M. G.
    Brown, M.
    Cameron, R. G.
    Blendis, L. M.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2007, 31 (06) : 221A - 221A
  • [37] Non-alcoholic steatohepatitis in children
    Nanda, K
    PEDIATRIC TRANSPLANTATION, 2004, 8 (06) : 613 - 618
  • [38] Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Eslami, Layli
    Merat, Shahin
    Malekzadeh, Reza
    Nasseri-Moghaddam, Siavosh
    Aramin, Hermineh
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [39] Non-Alcoholic Steatohepatitis Preface
    Harrison, Stephen A.
    CLINICS IN LIVER DISEASE, 2009, 13 (04) : XIII - XIV
  • [40] Statins and non-alcoholic steatohepatitis
    Athyros, Vasilios G.
    Katsiki, Niki
    Karagiannis, Asterios
    Mikhailidis, Dimitri P.
    JOURNAL OF HEPATOLOGY, 2016, 64 (01) : 241 - 242